Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia.


Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 29 08 2020
revised: 19 10 2020
accepted: 27 10 2020
pubmed: 8 12 2020
medline: 9 3 2021
entrez: 7 12 2020
Statut: ppublish

Résumé

In December 2019, the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and has since spread throughout the world. This study aimed to investigate the association between the change in laboratory markers during the three days after pneumonia diagnosis and severe respiratory failure in COVID-19 patients. Data of 23 COVID-19 patients with pneumonia, admitted to the Kumamoto City Hospital between February and April 2020 were retrospectively analyzed. Among the 23 patients, eight patients received mechanical ventilation (MV) (MV group), and the remaining 15 comprised the non-MV group. The levels of hemoglobin (Hb) and albumin (Alb) decreased in the MV group during the three days after pneumonia diagnosis more than in the non-MV group (median Hb: 1.40 vs. -0.10 g/dL, P = 0.015; median Alb: 0.85 vs. -0.30 g/dL, P = 0.020). Univariate logistic regression analysis showed that the decrease in Hb was associated with receiving MV care (odds ratio: 0.313, 95% confidence interval: 0.100-0.976, P = 0.045). Receiver operating characteristic curve analyses showed that the optimal cut-off value for the decrease in Hb level was -1.25 g/dL, with sensitivity and specificity values of 0.867 and 0.750, respectively. The decrease in Hb level during the short period after pneumonia diagnosis might be a predictor of worsening pneumonia in COVID-19 patients.

Sections du résumé

BACKGROUND BACKGROUND
In December 2019, the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and has since spread throughout the world. This study aimed to investigate the association between the change in laboratory markers during the three days after pneumonia diagnosis and severe respiratory failure in COVID-19 patients.
METHODS METHODS
Data of 23 COVID-19 patients with pneumonia, admitted to the Kumamoto City Hospital between February and April 2020 were retrospectively analyzed.
RESULTS RESULTS
Among the 23 patients, eight patients received mechanical ventilation (MV) (MV group), and the remaining 15 comprised the non-MV group. The levels of hemoglobin (Hb) and albumin (Alb) decreased in the MV group during the three days after pneumonia diagnosis more than in the non-MV group (median Hb: 1.40 vs. -0.10 g/dL, P = 0.015; median Alb: 0.85 vs. -0.30 g/dL, P = 0.020). Univariate logistic regression analysis showed that the decrease in Hb was associated with receiving MV care (odds ratio: 0.313, 95% confidence interval: 0.100-0.976, P = 0.045). Receiver operating characteristic curve analyses showed that the optimal cut-off value for the decrease in Hb level was -1.25 g/dL, with sensitivity and specificity values of 0.867 and 0.750, respectively.
CONCLUSIONS CONCLUSIONS
The decrease in Hb level during the short period after pneumonia diagnosis might be a predictor of worsening pneumonia in COVID-19 patients.

Identifiants

pubmed: 33281114
pii: S2212-5345(20)30160-X
doi: 10.1016/j.resinv.2020.10.009
pmc: PMC7682330
pii:
doi:

Substances chimiques

Biomarkers 0
Hemoglobins 0
Serum Albumin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-193

Informations de copyright

Copyright © 2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflict of interest.

Auteurs

Moriyasu Anai (M)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Kimitaka Akaike (K)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan. Electronic address: demio0601@gmail.com.

Hajime Iwagoe (H)

Department of Infectious Disease Internal Medicine, Kumamoto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Takefumi Akasaka (T)

Department of Emergency, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Takushi Higuchi (T)

Department of Anesthesiology, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Aoi Miyazaki (A)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Daiki Naito (D)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Yuka Tajima (Y)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Hiroshi Takahashi (H)

Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Taiyo Komatsu (T)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Aiko Masunaga (A)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan; Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Hiroto Kishi (H)

Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Kazuhiko Fujii (K)

Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Koichiro Fukuda (K)

Department of Respiratory Medicine, Kumamto City Hospital, 4-1-60 Higashi-machi, Higashi-ku, Kumamoto 862-8505, Japan.

Yusuke Tomita (Y)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Sho Saeki (S)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Hidenori Ichiyasu (H)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Takuro Sakagami (T)

Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH